Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.81 |
| ▸ | CNR1 | P21554 | 11/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
| ▸ | CASP1 | P29466 | 1/20 | 0.81 |
| ▸ | CASP7 | P55210 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3736014 | 0.90 | CNR2 (1.00) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL8270651 | 0.87 | CNR2 (0.86) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL7123280 | 0.85 | CNR2 (0.90) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL6746977 | 0.80 | CNR2 (0.82) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL7640834 | 0.78 | CNR2 (0.74) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL6748804 | 0.76 | CNR2 (0.75) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL4653103 | 0.73 | CNR1 (0.67) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL7638171 | 0.72 | CNR2 (0.69) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL4651950 | 0.72 | CNR2 (0.65) | CNR2CNR1CYP3A4MAPTALOX15 | |
| SCHEMBL4651843 | 0.71 | CNR2 (0.64) | CNR2CNR1CYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20100190793-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20070275970-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070270450-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190793-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | CNR2 90/4885CNR1 93/4885CYP3A4 3921/4885 |
| US-20070275970-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | CNR2 90/4885CNR1 93/4885CYP3A4 3921/4885 |
| US-20120010232-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | CNR2 90/4885CNR1 93/4885CYP3A4 3921/4885 |
| US-20070270450-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | MC4R, MC3R, MC5R | CNR2 90/4885CNR1 93/4885CYP3A4 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.